Description
Romidepsin is a depsipeptide prodrug that inhibits histone deacetylases (HDACs). Romidepsin is currently in clinical trials as a potential treatment for T-cell lymphomas; it displays anticancer chemotherapeutic and antiviral activities. Romidepsin enhances in vitro and in vivo natural killer (NK) cell cytotoxicity by increasing MIC A/B (NK ligand) expression on tumor cells in leukemia and lymphoma models. Romidepsin also induces G0/G1 phase cell cycle arrest and apoptosis, upregulates expression of p21 and p53, downregulates expression of MMP2 and MMP9, and inhibits cell proliferation in non-small cell lung cancer (NSCLC) cells. In vitro, this product also induces HIV expression from infected CD4+ T cells, decreasing persistent latent HIV reservoirs.